In vitro and in silico Screening of Bioactive Compounds from Jasminum subtriplinerve Blume as α-glucosidase Inhibitor
Abstract
The leaves of Jasminum subtriplinerve Blume were extracted by cold maceration with ethanol 70 % and subsequently fractionated with n-hexane, ethyl acetate (EtOAc), and n-butanol (n-BuOH) solvents. The extract and fractions were evaluated α-glucosidase inhibitory activities in vitro. The results have shown that n-hexane and EtOAc fractions had strong α-glucosidase inhibitory effects with IC50 values of 7.27 ± 0.71 mg/mL and 7.42 ± 0.95 mg/mL, respectively. The total extract, the n-BuOH fraction, and the aqueous fraction did not show inhibitory effects on the enzyme α-glucosidase. The molecular docking results revealed that rutin, isoverbascoside, astragalin, isoquercitrin, verbascoside, stigmasterol, nicotiflorin, and chevangin B might play an important role in the biological effect of this medicinal plant. Among these compounds, astragalin, isoquercitrin, verbascoside, and stigmasterol may be developed as drugs. Our findings suggested that leaves of Jasminum subtriplinerve Blume will be the potent resource of natural α-glucosidase inhibitors.
Keywords: α- glucosidase, diabetes, Jasminum subtriplinerve, molecular docking.
References
[1] S. Murugesu, Z. Ibrahim, Q. U. Ahmed, N. I. N. Yusoff, B. F. Uzir, V. Perumal et al., Characterization of Α-Glucosidase Inhibitors from Clinacanthus Nutans Lindau Leaves by Gas Chromatography-Mass Spectrometry-Based Metabolomics and Molecular Docking Simulation, Molecules, Vol, 23, No. 2402, 2018, pp. 1-21.[2] H. Sun, P. Saeedi, S. Karuranga,…
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.